David Calianese

David Calianese

Auto-generated profile, based on publicly available information

David Calianese

Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
FFortunato Ferrara
Fortunato Ferrara
MEM. Frank Erasmus
M. Frank Erasmus
SDSara D’aNgelo
Sara D’aNgelo
CLCamila Leal-Lopes
Camila Leal-Lopes
ATAndré A. Teixeira
André A. Teixeira
ABAndrew Bradbury
Andrew Bradbury
As a result of the SARS-CoV-2 pandemic numerous scientific groups have generated antibodies against a single target: the CoV-2 spike antigen. This has provided an unprecedented opportunity to compare the efficacy of different methods and the specificities and qualities of the antibodies generated by those methods. Generally, the most potent neutralizing antibodies have been generated from convalescent patients and immunized animals, with non-immune phage libraries usually yielding significantly less potent antibodies. Here, we show that it is possible to generate ultra-potent (IC50 < 2 ng/ml) human neutralizing antibodies directly from a unique semisynthetic naïve antibody library format with affinities, developability properties and neutralization activities comparable to the best from hyperimmune sources. This demonstrates that appropriately designed and constructed naïve antibody libraries can effectively compete with immunization to directly provide therapeutic antibodies against a viral pathogen, without the need for immune sources or downstream optimization.

15 July 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
DCDavid Calianese
David Calianese
TKTamara Kreiss
Tamara Kreiss
CKCanan Kasikara
Canan Kasikara
VDViralkumar Davra
Viralkumar Davra
KLKevin C Lahey
Kevin C Lahey
CAChoudhary Alok
Choudhary Alok
Phosphatidylserine (PS)-targeting monoclonal Abs (mAbs) that directly target PS and target PS via β2-gp1 (β2GP1) have been in preclinical and clinical development for over 10 y for the treatment of infectious diseases and cancer. Although the intended targets of PS-binding mAbs have traditionally included pathogens as well as stressed tumor cells and its associated vasculature in oncology, the effects of PS-targeting mAbs on activated immune cells, notably T cells, which externalize PS upon Ag stimulation, is not well understood. Using human T cells from healthy donor PBMCs activated with an anti-CD3 + anti-CD28 Ab mixture (anti-CD3/CD28) as a model for TCR-mediated PS externalization and T cell stimulation, we investigated effects of two different PS-targeting mAbs, 11.31 and bavituximab (Bavi), on TCR activation and TCR-mediated cytokine production in an ex vivo paradigm. Although 11.31 and Bavi bind selectivity to anti-CD3/28 activated T cells in a PS-dependent manner, surprisingly, they display distinct functional activities in their effect on IFN-γ and TNF-ɑ production, whereby 11.31, but not Bavi, suppressed cytokine production. This inhibitory effect on anti-CD3/28 activated T cells was observed on both CD4+ and CD8+ cells and independently of monocytes, suggesting the effects of 11.31 were directly mediated by binding to externalized PS on activated T cells. Imaging showed 11.31 and Bavi bind at distinct focal depots on the cell membrane. Collectively, our findings indicate that PS-targeting mAb 11.31 suppresses cytokine production by anti-CD3/28 activated T cells. Key Points PS-targeting mAbs 11.31 and Bavi bind external PS on anti-CD3/CD28 activated T cells. PS-binding mAb 11.31 suppresses anti-CD3/CD28 mediated cytokine production. Our findings implicate external PS as a regulatory target on activated T cells.

12 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
FFortunato Ferrara
Fortunato Ferrara
MEM. Frank Erasmus
M. Frank Erasmus
SDSara D’aNgelo
Sara D’aNgelo
CLCamila Leal-Lopes
Camila Leal-Lopes
ATAndré A. Teixeira
André A. Teixeira
ABAndrew Bradbury
Andrew Bradbury

15 February 2022 in medRxiv
Verified
Preprint
Open access
PDF file
CAChoudhary Alok
Choudhary Alok
MLMark Lerman
Mark Lerman
DCDavid Calianese
David Calianese
SKSalman Khan
Salman Khan
JHJudson Hunt
Judson Hunt
APAbraham Pinter
Abraham Pinter
Background: Multiple factors affecting COVID19 vaccine induced antibody responses in SARS-CoV2 uninfected immunosuppressed solid organ transplant recipients have been reported; however, there is still a lack of information on non-ACE2 competing cross-CoV2 neutralizing functional antibodies induced in these cohorts, and similarly the vaccine efficacy in prior CoV2-infected immunosuppressed individuals is not well understood. Methods: COVID19 vaccine efficacy was compared in a panel of kidney and heart transplant recipients who were either CoV2 uninfected (n=63) or CoV2 infected (n=13) prior to receiving two or three doses of mRNA vaccines using pseudoviral neutralization assays against eight CoV2 strains (the CoV2_D614G ancestral strain, alpha, beta, gamma, delta, kappa, lambda, and omicron-BA1 variants), while plasma antibody titers were determined by ELISA using recombinant CoV2-RBD-wt proteins. Results: Minimally protective neutralizing plasma antibody titers (IC 50 ≥ 1:50) against the variants were recorded 7-14% and 25-35% after the second and third doses respectively, with Omicron being the most resistant. In contrast, all previously infected vaccinees possessed minimal protective plasma titers against D614G after either two or three vaccine doses, with 11/13 exhibiting strong protection (IC50≥ 1:500) and 10/13 exceeding the minimal protective titer against Omicron. Absorption of the selected plasma with immobilized parental RBD removed ≥ 90% of its neutralizing activity, indicating that the dominant neutralization targets were in the RBD. Conclusions: This study showed that CoV2 infection followed by vaccination, but not vaccination alone, induces the presence of potent highly cross-reactive CoV2 neutralizing plasma antibodies that extend to Omicron variants, even in immunosuppressed SOTRs.

4 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
CAChoudhary Alok
Choudhary Alok
DCDavid Calianese
David Calianese
WHWilliam Honnen
William Honnen
AKAfsal Kolloli
Afsal Kolloli
RDRyan J Dikdan
Ryan J Dikdan
APAbraham Pinter
Abraham Pinter
The increasing prevalence of the highly antibody-evasive Omicron sublineages increases the risk of breakthrough infections and leaves high-risk and vulnerable immunocompromised individuals with no effective options for prophylactic or therapeutic antibody treatments. Here, we report a heavily mutated anti-RBD monoclonal antibody, Acovimab, directed against a site in the receptor-binding motif (RBM) region of the CoV2 receptor-binding domain (RBD), that possesses very broad and highly potent neutralizing activity against CoV2 variants, including many Omicron variants. This antibody is derived from the IGHV1-58*01 germline sequence and possesses a relatively high level of mutation (15.5% of the VH aa sequence), which is unusual for anti-RBD antibodies. Neutralizing activity was very potent (IC50s range of 1-9 ng/ml) for early Omicron subvariants that possess an unmutated F486 residue and is retained but less potent (IC50s of 200-650 ng/ml) for more resistant Omicron subvariants which contain the F486V mutation (BA4/5, BA4.6, and BQ1.1), but is lost for the later ultra-resistant variants that contain F486S (XBB) or F486P (XBB.1.5) mutations. Based on these specificities, it is predicted that Acovimab by itself should protect against CoV2 infections other than those caused by the XBB/XBB.1.5 family. Acovimab also shows strong synergy in neutralization when combined with Sotrovimab, which neutralizes all Omicron variants, including XBB.1.5. Plasma from subjects with hybrid immunity (induced by vaccination + infection) possessed low levels of XBB.1.5 RBM-targeting plasma-neutralizing antibodies, and these also neutralized synergistically when combined with Sotrovimab. These results suggest potentially novel immunotherapeutic options for treating most of the CoV2 variants responsible for current infections.